Notification about latest news from us.
WuXi Biologics is selling its Irish vaccine facility to Merck for $500 million amid potential US restrictions on Chinese biotech firms.
WuXi Biologics sells its Irish vaccine facility to Merck for $500 million as US restrictions on Chinese biotech loom.
UK approves Merck's sotatercept therapy, enhancing treatment for rare lung disease, following successful U.S. and EU approvals.
By clicking send you'll receive occasional emails from newsletters about this topic.